Comparison of Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-based Pulsed-field Ablation

Study design This is a single-center, randomized clinical study enrolling consecutive paroxysmal or persistent AF patients undergoing PVI with a B-PFA catheter (ClinicalTrials.gov identifier: pending). Patients will be randomized in a 1:1 basis to a fluoroscopy-only strategy vs. a strategy based on the same fluoroscopy workflow but with the addition of electroanatomic mapping (EAM).

Procedures will be carried out under deep sedo-analgesia with propofol and fentanyl. Patients will be scheduled for systematic, invasive remapping of the left atrium (LA) and pulmonary veins (PVs) a minimum of 30 days after index ablation, regardless of recurrence status.

The study will be carried out in University Hospital 12 de Octubre, a tertiary academic hospital, and has already received approval from the corresponding Institutional Review Board (code 23/208, mod. 2).

Patient data will be handled according to the current General Data Protection Regulation 2016/679 of the European Parliament (EU-GDPR) and the Council of 27 April 2016 on Personal Data Protection as well as national and local regulations regarding patient autonomy, and rights and obligations in terms of information and clinical documentation.

After a run-in phase of 10 cases per operator, 96 patients will be consecutively enrolled during a 4-month period (Figure 1).

Randomization Patients who meet all eligibility criteria and provide informed consent will be assigned in a 1:1 ratio to one of two treatment arms: (1) PVI using fluoroscopy-only as guidance (control group) or (2) PVI guided by fluoroscopy with the addition of EAM (experimental group). Randomization will be performed electronically at each participating center via the Research Electronic Data Capture (REDCap®) platform (Vanderbilt University, Nashville, TN, USA). A computer-generated permuted block sequence, with stratification by AF presentation (paroxysmal or persistent), will be used to ensure balanced allocation.

Study population Patients ≥18 years old, diagnosed with paroxysmal or persistent AF and clinical indication to undergo PVI will be included. Exclusion criteria are prior PVI or left atrial linear ablation, severe frailty or life expectancy <1 year, unwillingness or inability to provide informed consent, ablation at sites beyond PVI or indication for additional electrophysiological study, contraindication or intolerance to heparin, presence of left atrial thrombus, congenital heart disease, and pregnancy, ongoing or planned in the following 6 months.

Inclusion criteria

• ≥18 years old
• Diagnosed with paroxysmal or persistent AF
• Clinical indication to undergo PVI

Exclusion criteria

• Prior PVI or left atrial linear ablation
• Severe frailty or life expectancy <1 year
• Unwillingness or inability to provide informed consent
• Ablation at sites beyond PVI or indication for additional electrophysiological study
• Contraindication or intolerance to heparin
• Presence of left atrial thrombus
• Congenital heart disease
• Pregnancy, ongoing or planned in the following 6 months